TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
2020-03-11
SCID: 54.1/7epuj4wz
Abstract (AI)
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Key Findings
Research Object
Research Subject
Publication Details
Publication Date
2020-03-11
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF